| 4.45 0.14 (3.25%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.16 | 1-year : | 6.89 |
| Resists | First : | 5.28 | Second : | 5.9 |
| Pivot price | 4.59  |
|||
| Supports | First : | 4.28 | Second : | 3.56 |
| MAs | MA(5) : | 4.42 |
MA(20) : | 4.72 |
| MA(100) : | 5.81 |
MA(250) : | 5.38 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 12.5 |
D(3) : | 15 |
| RSI | RSI(14): 37.1 |
|||
| 52-week | High : | 7.65 | Low : | 4 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABEO ] has closed above bottom band by 34.5%. Bollinger Bands are 21.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.51 - 4.54 | 4.54 - 4.56 |
| Low: | 4.23 - 4.26 | 4.26 - 4.3 |
| Close: | 4.39 - 4.45 | 4.45 - 4.51 |
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Tue, 29 Sep 2026
Tax-related share sale: Abeona Therapeutics (ABEO) lists an officer’s shares for sale at a $34,682 value - Stock Titan
Mon, 28 Sep 2026
Abeona Therapeutics (NasdaqCM:ABEO) Stock Forecast & Analyst Predictions - Simply Wall Street
Tue, 08 Sep 2026
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law - Business Wire
Mon, 17 Aug 2026
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ... - Yahoo Finance
Thu, 13 Aug 2026
Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity (NASDAQ:ABEO) - Seeking Alpha
Thu, 13 Aug 2026
Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 3.609e+007 (%) |
| Held by Institutions | 10.9 (%) |
| Shares Short | 15,160 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.079e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -246.5 % |
| Operating Margin | -120 % |
| Return on Assets (ttm) | -24.6 % |
| Return on Equity (ttm) | -43.2 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 573.07 |
| Sales Per Share | 1.96308e+007 |
| EBITDA (p.s.) | -7.83077e+006 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -76 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.58 |
| Dividend | 0 |
| Forward Dividend | 1.688e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|